Skip to main content
SpringerLink
Log in

Pharmacological Treatment of Generalized Anxiety Disorder

  • Chapter
  • First Online:
Behavioral Neurobiology of Anxiety and Its Treatment

Part of the book series: Current Topics in Behavioral Neurosciences ((CTBN,volume 2))

Abstract

Generalized anxiety disorder (GAD) is common in community and clinical settings. The individual and societal burden associated with GAD is substantial, but many of those who could benefit from treatment are not recognized or treated. Recent evidence-based guidelines for the pharmacological management of patients with GAD have recommended initial treatment with either a selective serotonin reuptake inhibitor (SSRI) or a serotonin-norepinephrine reuptake inhibitor (SNRI), on the basis of their proven efficacy and reasonable tolerability in randomized placebo-controlled trials. However, there is much room for improvement in both the efficacy and the tolerability of treatment. Response rates to first-line treatment can be disappointing and it is hard to predict reliably which patients will respond well and which will have only a limited treatment response. Many patients worry about becoming dependent on medication, a substantial proportion experience troublesome adverse effects, and these problems limit the effectiveness of pharmacological treatments in clinical practice. The relative lack of longitudinal studies of clinical outcomes in GAD, and the small number of placebo-controlled relapse prevention studies lead to uncertainty about the optimal duration of treatment after a satisfactory initial response. There have been few investigations of the further management of patients who have not responded to first-line treatment and there is a pressing need for further augmentation studies in patients who have not responded to an SSRI or SNRI, or to other initial pharmacological approaches. Future treatment guidelines for GAD will be influenced by emerging data for established and novel pharmacological approaches, and possibly through the more accurate identification of certain patient subgroups who are likely to respond preferentially to particular interventions.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Allgulander C (2008) Presented at 21st ECNP Congress, 31st August 2008, Barcelona, Spain

    Google Scholar 

  • Allgulander C, Hackett D, Salinas E (2001) Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study. Br J Psychiatry 179:15–22

    Article  PubMed  CAS  Google Scholar 

  • Allgulander C, Dahl AA, Austin C et al (2004) Efficacy of sertraline in a 12-week trial for generalized anxiety disorder. Am J Psychiatry 161: 1642–1649

    Google Scholar 

  • Allgulander C, Florea I, Huusom AK (2006) Prevention of relapse in generalized anxiety disorder by escitalopram treatment. Int J Neuropsychopharmacol 9:495–505

    Article  PubMed  CAS  Google Scholar 

  • Angst J, Gamma A, Baldwin DS et al (2009) The generalized anxiety spectrum: prevalence, onset, course and outcome. Eur Arch Psychiatry Clin Neurosci 259: 37–45

    Google Scholar 

  • Baldwin DS (2004) Sexual dysfunction associated with antidepressant drugs. Exp Opin Drug Safety 3:457–470

    Article  CAS  Google Scholar 

  • Baldwin DS, Ajel K (2007) The role of pregabalin in the treatment of generalized anxiety disorder. Neuropsychiatric Dis Treat 3:185–191

    Article  CAS  Google Scholar 

  • Baldwin DS, Polkinghorn C (2005) Evidence-based pharmacotherapy of generalized anxiety disorder. Int J Neuropsychopharmacol 8:293–302

    Article  PubMed  CAS  Google Scholar 

  • Baldwin DS, Anderson IM, Nutt DJ et al (2005) Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British association for Psychopharmacology. J Psychopharmacol 19:567–596

    Article  PubMed  CAS  Google Scholar 

  • Baldwin DS, Huusom AKT, Maehlum E (2006a) Escitalopram and paroxetine in the treatment of generalised anxiety disorder. Randomised, double-blind, placebo-controlled study. Br J Psychiatry 189:264–272

    Article  PubMed  Google Scholar 

  • Baldwin DS, Bridgman K, Buis C (2006b) Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine. J Psychopharmacol 20:91–96

    Article  PubMed  CAS  Google Scholar 

  • Baldwin DS, Reines EH, Guiton C et al (2007a) Escitalopram therapy for major depression and anxiety disorders. Ann Pharmacother 41:1583–1592

    Article  PubMed  CAS  Google Scholar 

  • Baldwin DS, Montgomery SA, Nil R et al (2007b) Discontinuation symptoms in depression and anxiety disorders. Int J Neuropsychopharmacol 10:73–84

    Article  PubMed  CAS  Google Scholar 

  • Baldwin DS, Stein DJ, Dolberg O et al (2009) How long should an initial treatment period be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database. Hum Psychopharmacol 24:269–275

    Google Scholar 

  • Baldwin DS, Moreno R, Briley M (2008) Resolution of sexual dysfunction during acute treatment of major depression with milnacipran. Hum Psychopharmacol 23:527–532

    Google Scholar 

  • Ballenger JC (1999) Clinical guidelines for establishing remission in patients with depression and anxiety. J Clin Psychiatry 60(suppl 22):29–34

    Google Scholar 

  • Bandelow B, Baldwin DS, Dolberg OT et al (2006) What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder? J Clin Psychiatry 67:1428–1434

    Article  PubMed  Google Scholar 

  • Bandelow B, Bobes J, Ahokas A, et al (2007a) Results from a phase III study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalised anxiety disorder. Int J Psychiatry Clin Pract 11:314–315 (abstract)

    Google Scholar 

  • Bandelow B, Seidler-Brandler U, Becker A et al (2007b) Meta-analysis of randomized controlled comparisons of psychopharmacological and psychological treatments for anxiety disorders. World J Biol Psychiatr 8:175–187

    Article  Google Scholar 

  • Bech P (2007) Dose-response relationship of pregabalin in patients with generalized anxiety disorder. A pooled analysis of four placebo-controlled trials. Pharmacopsychiatry 40:163–168

    Article  PubMed  CAS  Google Scholar 

  • Beekman AT, Bremmer MA, Deeg DJ et al (1998) Anxiety disorders in later life: a report from the longitudinal Aging Study Amsterdam. Int J Geriatr Psychiatry 13:717–726

    Article  PubMed  CAS  Google Scholar 

  • Brawman-Mintzer O, Knapp RG, Nietert PJ (2005) Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study. J Clin Psychiatry 66:1321–1325

    Article  PubMed  CAS  Google Scholar 

  • Brawman-Mintzer O, Knapp RG, Rynn M et al (2006) Sertraline treatment for generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 67:874–881

    Google Scholar 

  • Bruce SE, Yonkers KA, Otto MW et al (2005) Influence of psychiatric comorbidity on recovery and recurrence in generalized anxiety disorder, social phobia, and panic disorder: a 12-year prospective study. Am J Psychiatry 162:1179–1187

    Article  PubMed  Google Scholar 

  • Canadian Psychiatric Association (2006) Clinical practice guidelines. Management of anxiety disorders. Can J Psychiatr 51:9S–91S

    Google Scholar 

  • Carney CE, Segal ZV, Edinger JD et al (2007) A comparison of rates of residual insomnia symptoms following pharmacotherapy or cognitive-behavioral therapy for major depressive disorder. J Clin Psychiatr 68:254–260

    Article  CAS  Google Scholar 

  • Cervena K, Matousek M, Prasko J et al (2005) Sleep disturbances in patients treated for panic disorder. Sleep Med 6:149–153

    Article  PubMed  Google Scholar 

  • Chessick CA, Allen MH, Thase M et al (2006) Azapirones for generalized anxiety disorder. Cochrane Database Syst Rev 3:CD006115

    Google Scholar 

  • Davidson JR, DuPont RL, Hedges D et al (1999) Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. J Clin Psychiatry 60:528–535

    Google Scholar 

  • Davidson JR, Bose A, Korotzer A et al (2004) Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study. Depress Anxiety 19:234–240

    Google Scholar 

  • Davidson JRT, Wittchen H-U, Llorca P-M et al (2008) Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: a double-blind placebo-controlled trial. Eur Neuropsychopharmacol 18:673–681

    Article  PubMed  CAS  Google Scholar 

  • Downing RW, Rickels K (1985) Early treatment response in anxious outpatients treated with diazepam. Acta Psychiatr Scand 72:522–528

    Article  PubMed  CAS  Google Scholar 

  • Feltner D, Crockatt JG, Dubovsky SJ et al (2003) A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol 23:240–249

    Google Scholar 

  • Feltner D, Wittchen HU, Kavoussi R et al (2008) Long-term efficacy of pregabalin in generalized anxiety disorder. Int Clin Psychopharmacol 23:18–28

    Article  PubMed  Google Scholar 

  • Ferguson JM (2001) SSRI antidepressant medications: adverse effects and tolerability. Prim Care J Clin Psychiatry 3:22–27

    Article  Google Scholar 

  • Food and Drug Administration [FDA] (2006) New controversial clinical trial design gives better long-term data. FDA Week

    Google Scholar 

  • Geddes JR, Carney SM, Davies C et al (2003) Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 361:653–661

    Article  PubMed  CAS  Google Scholar 

  • Gelenberg AJ, Lydiard RB, Rudolph RL et al (2000) Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial. JAMA, 283: 3082–3088

    Google Scholar 

  • Goodman WK, Bose A, Wang Q (2005) Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials. J Affect Disord 87:161–167

    Google Scholar 

  • Gould RA, Otto MW, Pollack MH et al (1997) Cognitive behavioural and pharmacological treatment of generalised anxiety disorder: a preliminary meta-analysis. Behav Ther 28:285–305

    Article  Google Scholar 

  • Guy W (1976) The clinical global impression severity and impression scales. In: ECDEU Assessment Manual for Psychopathology. Rockville, MD. US Dept Health, Education and Welfare, 218–222

    Google Scholar 

  • Hamilton M (1959) The assessment of anxiety states by rating. Br J Med Psychol 32:50–55

    Article  PubMed  CAS  Google Scholar 

  • Hartford J, Kornstein S, Liebowitz M et al (2007) Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial. Int Clin Psychopharmacol 22:167–174

    Google Scholar 

  • Hidalgo RB, Tupler LA, Davidson JRT (2007) An effect-size analysis of pharmacologic treatments for generalized anxiety disorder. J Psychopharmacol 21:864–872

    Article  PubMed  CAS  Google Scholar 

  • Judd LL, Kessler RC, Paulus MP et al (1998) Comorbidity as a fundamental feature of generalized anxiety disorders: results from the National Comorbidity Survey (NCS). Acta Psychiatr Scand 98(Suppl 393):6–11

    Article  Google Scholar 

  • Kasper S, Herman B, Nivoli G et al (2009). Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial. Int Clin Psychopharmacol 2009. E-pub ahead of print. DOI: 10.1097/YIC.0b013e32831d7980

    Google Scholar 

  • Katzman MA, Vermani M, Jacobs L et al (2008) Quetiapine as an adjunctive pharmacotherapy for the treatment of non-remitting generalized anxiety disorder: a flexible-dose, open-label pilot trial. J Anxiety Disord [Epub ahead of print]

    Google Scholar 

  • Kessler RC, DuPont RL, Berglund (1999) Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys. Am J Psychiatry 156:1915–1923

    Google Scholar 

  • Kinrys G, Vasconcelos e Sa D, Nery F (2007) Adjunctive zonisamide for treatment refractory anxiety. Int J Clin Pract 61:1050–1053

    Google Scholar 

  • Laakmann G, Schüle C, Lorkowski G et al (1998) Buspirone and lorazepam in the treatment of generalized anxiety disorder in outpatients. Psychopharmacol 136:357–366

    Article  CAS  Google Scholar 

  • Lenox-Smith AJ, Reynolds A (2003) A double-blind, randomised, placebo controlled study of venlafaxine XL in patients with generalised anxiety disorder in primary care. Br J Gen Pract 53:772–777

    Google Scholar 

  • Martin JLR, Sainz-Pardo M, Furukawa TA et al (2007) Benzodiazepines in generalized anxiety disorder: heterogeneity of outcomes based on a systematic review and meta-analysis of clinical trials. J Psychopharmacol 21:774–782

    Article  PubMed  CAS  Google Scholar 

  • Mendels J, Krajewski TF, Huffer V et al (1986) Effective short-term treatment of generalized anxiety disorder with trifluoperazine. J Clin Psychiatry 47:170–174

    PubMed  CAS  Google Scholar 

  • Meredith C, Cutler A, Neijber A, She F, Eriksson H (2008) Efficacy and tolerability of extended release quetiapine fumarate monotherapy in the treatment of GAD. Eur Neuropsychopharmacol 18(suppl 4):S499–S450

    Article  Google Scholar 

  • Miceli JJ, Ramey TS, Weaver JJ et al (2009) Adjunctive pregabalin treatment after partial response in generalized anxiety disorder: results of a double-blind, placebo-controlled trial. Presented at the 162nd Annual Meeting of the American Psychiatric Association; May 16–21, 2009; San Francisco, CA

    Google Scholar 

  • Mitte K, Noack P, Steil R, Hautzinger M (2005) A meta-analytic review of the efficacy of drug treatment in generalized anxiety disorder. J Clin Psychopharmacol 25:141–150

    Article  PubMed  CAS  Google Scholar 

  • Montgomery SA, Sheehan DV, Meoni P et al (2002) Characterization of the longitudinal course of improvement in generalized anxiety disorder during long-term treatment with venlafaxine XR. J Psychiatr Res 36:209–217

    Article  PubMed  Google Scholar 

  • Montgomery SA, Tobias K, Zornberg GL et al (2006) Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J Clin Psychiatry 67:771–782

    Google Scholar 

  • Montgomery S, Chatamra K, Pauer L et al (2008) Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder. Br J Psychiatry 193:389–394

    Google Scholar 

  • Nutt DJ (2005) Overview of diagnosis and drug treatment of anxiety disorders. CNS Spectrums 10:49–56

    PubMed  Google Scholar 

  • Olatunji BO, Feldman G, Smits JAJ et al (2008) Examination of the decline in symptoms of anxiety and depression in generalized anxiety disorder: impact of anxiety sensitivity on response to pharmacotherapy. Depress Anx 25:167–171

    Article  CAS  Google Scholar 

  • Pande AC, Crockatt MA, Janney C et al (2000) Pregabalin treatment of GAD. Presented at: American Psychiatric Association 153rd Annual Meeting. May 13–18; Chicago, IL (Abstract NR244). Available at: http://www.psych.org/edu/other_res/lib_archives/archives/meetings/2000nra.pdf Accessed February 15, 2006

  • Pande AC, Crockatt JG, Feltner DE et al (2003) Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiatry 160:533–540

    Google Scholar 

  • Perugi G, Frare F, Toni C et al (2002) Open-label evaluation of venlafaxine sustained release in outpatients with generalized anxiety disorder with comorbid depression or dysthymia: effectiveness, tolerability and predictors of response. Neuropsychobiol 46:145–149

    Article  CAS  Google Scholar 

  • Pohl RB, Feltner DE, Fieve RR et al (2005) Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing. J Clin Psychopharmacol 25:151–158

    Google Scholar 

  • Pollack MH, Zaninelli R, Goddard A et al (2001) Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry 62:350–357

    Google Scholar 

  • Pollack MH, Meoni P, Otto MW et al (2003) Predictors of outcome following venlafaxine extended-release treatment of DSM-IV generalized anxiety disorder: a pooled analysis of short- and long-term studies. J Clin Psychopharmacol 23:250–259

    PubMed  CAS  Google Scholar 

  • Pollack MH, Simon NM, Zalta AK et al (2006) Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study. Biol Psychiatry 59:211–215

    Article  PubMed  CAS  Google Scholar 

  • Pollack MH, Kornstein SG, Spann ME, et al (2008) Early improvement during duloxetine treatment of generalized anxiety disorder predicts response and remission at endpoint. J Psychiatr Res [Epub ahead of print]

    Google Scholar 

  • Rickels K, Schweizer E, Csanalosi I et al (1988) Long-term treatment of anxiety and risk of withdrawal: prospective study of clorazepate and buspirone. Arch Gen Psychiatr 45:444–450

    Article  PubMed  CAS  Google Scholar 

  • Rickels K, Pollack MH, Sheehan DV et al (2000) Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am J Psychiatry 157:968–974

    Article  PubMed  CAS  Google Scholar 

  • Rickels K, Zaninelli R, McCafferty J et al (2003) Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. Am J Psychiatry 160:749–756

    Article  PubMed  Google Scholar 

  • Rickels K, Pollack MH, Feltner DE et al (2005) Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry 62:1022–1030

    Google Scholar 

  • Rickels K, Rynn M, Iyengar M et al (2006) Remission of generalized anxiety disorder: a review of the paroxetine clinical trials database. J Clin Psychiatry 67:41–47

    Article  PubMed  CAS  Google Scholar 

  • Rodriguez BF, Weisberg RB, Pagano ME et al (2006) Characteristics and predictors of full and partial recovery from generalized anxiety disorder in primary care patients. J Nerv Ment Dis 194:91–97

    Article  PubMed  Google Scholar 

  • Rynn MA, Siqueland L, Rickels K (2001) Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder. Am J Psychiatry158:2008–2014

    Google Scholar 

  • Rynn M, Khalid-Khan S, Garcia-Espana F (2006) Early response and 8-week treatment outcome in GAD. Depress Anx 23:461–465

    Article  CAS  Google Scholar 

  • Rynn MA, Riddle MA, Yeung PP et al (2007) Efficacy and safety of extended-release venlafaxine in the treatment of generalized anxiety disorder in children and adolescents: two placebo-controlled trials. Am J Psychiatry 164:290–300

    Google Scholar 

  • Rynn M, Russell J, Erickson J et al (2008) Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial. Depress Anxiety 25:182–189

    Google Scholar 

  • Simon NM, Zalta AK, Worthington JJ 3rd et al (2006) Preliminary support for gender differences in response to fluoxetine for generalized anxiety disorder. Depress Anx 23:373–376

    Article  CAS  Google Scholar 

  • Simon NM, Connor KM, LeBeau RT et al (2008) Quetiapine augmentation of paroxetine CR for the treatment of generalized anxiety disorder: preliminary findings. Psychopharmacol (Berl) 197:675–681

    Google Scholar 

  • Stein DJ, Andersen HF, Goodman WK (2005) Escitalopram for the treatment of GAD: efficacy across different subgroups and outcomes. Ann Clin Psychiatry 17:71–75

    Article  PubMed  Google Scholar 

  • Stein DJ, Baldwin DS, Dolberg OT et al (2006) Which factors predict placebo response in anxiety disorders and major depression? An analysis of placebo-controlled studies of escitalopram. J Clin Psychiatry 67:1741–1746

    Article  PubMed  CAS  Google Scholar 

  • Stein DJ, Ahokas A, de Bodinat C (2008b) Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 28:561–566

    Article  Google Scholar 

  • Stein DJ, Baldwin DS, Baldinetti F, Baldinetti F, Mandel F (2008a) Efficacy of pregabalin in depressive symptoms associated with generalized anxiety disorder: a pooled analysis of 6 studies. Eur Neuropsychopharmacol 18:422–430

    Article  PubMed  CAS  Google Scholar 

  • Stocchi F, Nordera G, Jokinen RH et al (2003) Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder. J Clin Psychiatry 64:250–258

    Article  PubMed  CAS  Google Scholar 

  • Tyrer P, Baldwin DS (2006) Generalised anxiety disorder. Lancet 368:2156–2166

    Article  PubMed  Google Scholar 

  • Tyrer P, Owen R, Dawling S (1983) Gradual withdrawal of diazepam after long-term therapy. Lancet 321:1402–1406

    Article  Google Scholar 

  • Tyrer P, Seivewright H, Johnson T (2004) The Nottingham Study of Neurotic Disorder: predictors of 12 year outcome of dysthymic, panic and generalised anxiety disorder. Psychol Med 34:385–394

    Article  Google Scholar 

  • Weiller E, Bisserbe JC, Maier W et al (1998) Prevalence and recognition of anxiety syndromes in five European primary care settings. A report from the WHO Study on Psychological Problems in General Health Care. Br J Psychiatr 173(suppl 34):18–23

    Google Scholar 

  • Wittchen H-U, Jacobi F (2005) Size and burden of mental disorders in Europe: a critical review and appraisal of 27 studies. Eur Neuropsychopharmacol 15:357–376

    Article  PubMed  CAS  Google Scholar 

  • Wittchen H-U, Carter RM, Pfisster H, Montgomery SA et al (2000) Disabilities and quality of life in pure and comorbid generalized anxiety disorder and major depression in a national survey. Int Clin Psychopharmacol 15:319–328

    Article  PubMed  CAS  Google Scholar 

  • Wittchen H-U, Kessler RC, Beesdo K et al (2002) Generalized anxiety disorder and depression in primary care: prevalence, recognition, and management. J Clin Psychiatry 63(suppl 8):24–34

    PubMed  Google Scholar 

Download references

Acknowledgments

This review is based upon a talk given at the 20th ECNP Congress, Vienna, Austria, the abstract for which was published as Baldwin DS, Ajel KI, Garner MJ (2007) Eur Neuropsychopharmacol 17(Suppl 4):S208.

Author information

Authors and Affiliations

  1. Clinical Neuroscience Division, School of Medicine, University of Southampton, Southampton, UK

    David S. Baldwin

  2. University Department of Mental Health, Royal South Hants Hospital, Brintons Terrace, Southampton, SO14 0YG, UK

    David S. Baldwin

  3. Mood and Anxiety Disorders Service, Hampshire Partnership Trust, Southampton, UK

    Khalil I. Ajel

  4. School of Psychology, University of Southampton, Southampton, UK

    Matthew Garner

Authors
  1. David S. Baldwin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Khalil I. Ajel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Matthew Garner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David S. Baldwin .

Editor information

Editors and Affiliations

  1. Dept. Psychiatry, University of California, San Diego, Gilman Drive 9500, La Jolla, 92093-0985, USA

    Murray B. Stein

  2. Research & Development, CNS - Affective Spectrum, Johnson & Johnson Pharmaceutical, Turnhoutseweg 30, Beerse, 2340, Belgium

    Thomas Steckler

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Baldwin, D.S., Ajel, K.I., Garner, M. (2009). Pharmacological Treatment of Generalized Anxiety Disorder. In: Stein, M., Steckler, T. (eds) Behavioral Neurobiology of Anxiety and Its Treatment. Current Topics in Behavioral Neurosciences, vol 2. Springer, Berlin, Heidelberg. https://doi.org/10.1007/7854_2009_2

Download citation

Publish with us

Policies and ethics

Search

Navigation